Th17 Cancer Research Results

Th17, T helper 17 (Th17) cells: Click to Expand ⟱
Source:
Type:
Th17 cells are a distinct subset of CD4+ T helper cells characterized by their production of interleukin-17 (IL-17) family cytokines (most notably IL-17A and IL-17F), as well as other effector molecules like IL-21 and IL-22. These cells play a key role in mediating inflammatory responses and defending against extracellular pathogens, particularly fungi and bacteria.

Th17 cells have been reported to exhibit both pro-tumor and anti-tumor properties:
  – Anti-Tumor Effects: In some contexts, the pro-inflammatory cytokines produced by Th17 cells can enhance anti-tumor immunity by recruiting and activating other immune cells (e.g., cytotoxic T lymphocytes and natural killer cells).
  – Pro-Tumor Effects: Conversely, chronic inflammation driven by Th17 cells may promote tumor progression by encouraging angiogenesis, suppressing effective anti-tumor immune responses, or by directly supporting tumor cell survival and metastasis.
Scientific Papers found: Click to Expand⟱
2690- BBR,    Berberine Differentially Modulates the Activities of ERK, p38 MAPK, and JNK to Suppress Th17 and Th1 T Cell Differentiation in Type 1 Diabetic Mice
- in-vivo, Diabetic, NA
*Inflam↓, Recent studies suggested that berberine has many beneficial biological effects, including anti-inflammation.
*Th17↓, Here we reported that 2 weeks of oral administration of berberine prevented the progression of type 1 diabetes in half of the NOD mice and decreased Th17 and Th1 cytokine secretion.
*Th1 response↓,
*ERK↑, berberine inhibited Th17 differentiation by activating ERK1/2 and inhibited Th1 differentiation by inhibiting p38 MAPK and JNK activation.
*p38↓,
*JNK↓,
*STAT1↓, Berberine down-regulated the activity of STAT1 and STAT4 through the suppression of p38 MAPK and JNK activation,
*STAT4↓,
*MAPK↓,

1197- MAG,    Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells
- in-vivo, MS, NA
Weight↑, alleviated loss of body weight
Th17↓,
STAT3↓, potential of magnolol for treating MS as novel STAT3 inhibitor.


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State ⓘ

STAT3↓, 1,  

Immune & Inflammatory Signaling ⓘ

Th17↓, 1,  

Functional Outcomes ⓘ

Weight↑, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Cell Death ⓘ

JNK↓, 1,   MAPK↓, 1,   p38↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,   STAT1↓, 1,   STAT4↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   Th1 response↓, 1,   Th17↓, 1,  
Total Targets: 9

Scientific Paper Hit Count for: Th17, T helper 17 (Th17) cells
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1043  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page